PURPOSE: To date, @entity136 -based or fluoropyrimidine-based regimens are recommended for unresectable advanced @entity1125 . Then, we conducted a phase I study of @entity136 / @entity900 and @entity11730 that is an oral fluoropyrimidine. The aim of this study was to determine the dose-limiting @entity137 (DLT), maximum-tolerated dose, and a recommended phase II dose of @entity11730 . Response was assessed as a secondary endpoint. @entity1 AND METHODS: @entity1 who have been diagnosed with unresectable or postoperative recurrent @entity1125 received @entity900 (25  mg/m(2) i.v. for 120  min) followed by @entity136 (1,000  mg/m(2) i.v. for 30  min) on days 1 and 8, and oral @entity11730 on alternate days; this regimen was repeated at 21-day intervals. A standard '3  +  3' phase I dose-escalation design was adopted. This study was registered with University hospital Medical Information Network (UMIN) Center in Japan, number UMIN000008415. RESULTS: Twelve @entity1 were evaluable in this study. No @entity1 developed DLTs. Recommended dose of @entity11730 was 80 (<1.25  m(2)), 100 (1.25   <=  1.5  m(2)), and 120  mg (1.5  m(2)>= ) per day. One @entity1 could achieve conversion to curative surgery. CONCLUSION: This phase I study was performed safely and demonstrated encouraging response.

Phase I trial of @entity11730 every other day in combination with @entity136 / @entity900 for inoperable XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity11730 :: ('5707', 'Gene') :: ['S-1'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1125 :: ('MESH:D001661', 'Disease') :: ['biliary tract cancer']
@entity1125 :: (MESH:D001661,Disease) :: ['biliary tract cancer']
